IM Cannabis (IMCC) Other Non-Current Liabilities (2023 - 2024)
IM Cannabis (IMCC) posted quarterly Other Non-Current Liabilities of $1.5 million for Q1 2024, down 26.31% quarter-over-quarter from $2.0 million in Q4 2023.
IM Cannabis (IMCC) Other Non-Current Liabilities (2023 - 2024) Analysis & Trends
IM Cannabis' Other Non-Current Liabilities history runs 2 years deep, the most recent figure standing at $1.5 million for Q1 2024.
- In Q1 2024, Other Non-Current Liabilities changed N/A year-over-year to $1.5 million; the TTM figure through Mar 2024 stood at $1.5 million (changed N/A YoY), while the FY2023 annual figure was $2.0 million, changed N/A from the prior year.
- Other Non-Current Liabilities for Q1 2024 stood at $1.5 million, down from $2.0 million in the prior quarter.
- The five-year high for Other Non-Current Liabilities was $2.0 million in Q4 2023, with the low at $1.5 million in Q1 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - |
| 10 | IM Cannabis | 549,631.99 | -619,338.18 | 1.09 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2024 | 1.46 Mn |
| Dec 31, 2023 | 1.98 Mn |